NASDAQ:DRRX - DURECT Stock Price, Forecast & News

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Monday, November, 4th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.03. The specialty pharmaceutical company had revenue of $10.76 million for the quarter, compared to analysts' expectations of $7.78 million. DURECT had a negative return on equity of 119.34% and a negative net margin of 105.07%. View DURECT's Earnings History.

DURECT is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for DURECT.

5 analysts have issued twelve-month price objectives for DURECT's stock. Their forecasts range from $2.10 to $5.50. On average, they anticipate DURECT's share price to reach $4.40 in the next year. This suggests a possible upside of 120.0% from the stock's current price. View Analyst Price Targets for DURECT.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.

News stories about DRRX stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. DURECT earned a media sentiment score of -3.7 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for DURECT.

DURECT saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 5,190,000 shares, an increase of 26.0% from the January 15th total of 4,120,000 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is presently 3.8 days. Currently, 3.3% of the company's shares are short sold. View DURECT's Current Options Chain.

Some companies that are related to DURECT include Constellation Pharmaceuticals (CNST), Amneal Pharmaceuticals (AMRX), Nabriva Therapeutics (NBRV), Dicerna Pharmaceuticals (DRNA), Zogenix (ZGNX), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT) and Athenex (ATNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Cassava Sciences (SAVA), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Amarin (AMRN), Geron (GERN), Gilead Sciences (GILD), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Advanced Micro Devices (AMD).

DURECT's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.06%), Renaissance Technologies LLC (2.19%), Beirne Wealth Consulting Services LLC (0.86%), Gagnon Securities LLC (0.61%), Acadian Asset Management LLC (0.59%) and Panagora Asset Management Inc. (0.36%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder and Michael Arenberg. View Institutional Ownership Trends for DURECT.

DRRX stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Assenagon Asset Management S.A., Virtu Financial LLC, Gagnon Securities LLC, Cubist Systematic Strategies LLC and Citigroup Inc.. View Insider Buying and Selling for DURECT.

DRRX stock was bought by a variety of institutional investors in the last quarter, including EAM Global Investors LLC, EAM Investors LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Beirne Wealth Consulting Services LLC, Panagora Asset Management Inc., Alpine Global Management LLC and California Public Employees Retirement System. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder and Michael Arenberg. View Insider Buying and Selling for DURECT.

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DRRX stock can currently be purchased for approximately $2.00.

DURECT has a market capitalization of $384.72 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.View Additional Information About DURECT.

The official website for DURECT is http://www.durect.com/.

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.